natgillin/translations-raw huggingface dataset:
Close the jar and shake it carefully until all the powder is dissolved.
Tillslut behållaren och skaka försiktigt tills allt pulver är löst.
Close the label sealing the used patch within and discard, keeping out of reach of children.
Förslut etiketten med det använda plåstret inuti och kassera sedan utom syn- och räckhåll för barn.
Close the lid and shake hard for at least 90 seconds until all the lumps have dissolved.
Stäng locket och skaka hårt i minst 90 sekunder tills alla klumpar har löst upp sig.
Close the lid to seal the mixing cup.
Stäng locket för att försluta blandningskoppen.
Close the medicine reservoir by aligning the tabs of the medicine cap with the slots of the reservoir (a).
Stäng läkemedelsbehållaren genom att passa in flikarna på läkemedelslocket med spåren på läkemedelsbehållaren (a).
Close the tube tightly after each use.
Tillslut tuben väl efter varje användning.
Close your mouth and hold your breath for 5 seconds.
Stäng munnen och håll andan i 5 sekunder.
Close: Breathe out gently and close the mouthpiece cover
Stäng: Andas ut försiktigt och stäng skyddslocket till munstycket.
Closed pouches of fluid within the kidneys (kidney cysts).
Slutna, vätskefyllda hålrum inuti njurarna (komplexa njurcystor).
Closed shoes: for feet.
Täta skor: för fötter.
closely for a decreased VPA
för sänkta VPA-effekter då
Closely monitor all patients for signs and symptoms of pneumonitis.
Patienterna ska noga övervakas för tecken och symtom på pneumonit.
closing of the throat, difficulty swallowing
tillstängning av halsen, svårigheter att svälja
Clostridium difficile associated diarrhoea
Clostridium difficile-associerad diarré
Clostridium difficile associated diarrhoea (CDAD) has been reported for tedizolid phosphate (see section 4.8).
Clostridium difficile-associerad diarré (CDAD) har rapporterats för tedizolidfosfat (se avsnitt 4.8).
Clostridium difficile colitis; Mycobacterial infection (including tuberculosis); Epstein-Barr virus infection
Clostridium difficile kolit Mykobakteriell infektion (inklusive tuberkulos) Epstein-Barr- virusinfektion
Clostridium difficile colitis; Mycobacterial infection (including tuberculosis); Epstein-Barr virus infection
infektion (inklusive tuberkulos) Epstein-Barr- virusinfektion
Clostridium difficile-associated diarrhoea**
Clostridium difficile-associerad diarré
Clostridium difficile-associated disease
Clostridium difficile – associerad sjukdom
Clostridium perfringens component:
Clostridium perfringens-komponent:
Clostridium perfringens Type A alpha toxoid Not less than 6.8 IU *
Clostridium perfringens Typ A alfatoxoid Minst 6,8 IE
Clostridium perfringens Type A alpha toxoid: ≥ 6.8 IU* Light mineral oil: 0.31 ml
Clostridium perfringens Typ A alfatoxoid: ≥6,8 IE* Lättflytande mineralolja: 0,31 ml
Clostridium perfringens, a bacterium which may be involved in the development of ERE, isolated from rabbits with ERE showed MIC90 values of 0.5 g/ml.
Clostridium perfringens, ett bakterium som kan vara inblandat med utveckling av ERE, isolerat från kaniner med ERE visade MIC90-värden på 0,5 g/ml.
Clostridium species (excluding C. difficile)* Eubacterium species*
Clostridium-arter (undantaget C. difficile)* Eubacterium-arter
Clostridium tetani toxoid ............................................................................................................. ≥ 30 IU
Clostridium tetani toxoid .........................................................................................................  30 IU/ml
Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b.
Clostridium tetani, Bordetella pertussis, hepatit B-virus, poliovirus eller Haemophilus influenzae typ b.
closure and
mipropp
Closure of the potassium channels leads to depolarisation of the beta cell and results by opening of the calcium channels – to an increased influx of calcium into the cell.
Stängningen av kaliumkanalerna inducerar en depolisering av beta-cellerna, vilket i sin tur leder till att kalciumkanalerna öppnas och flödet av kalcium in i cellerna ökar.
clotting of an artificial kidney
Trombos i konstgjord njure
Clotting parameters (e.g.
Koagulationsparametrar (t.ex.
cloudiness of the eye surface (transient corneal opacity) yellowing of the skin or whites of the eyes (jaundice).
grumling av ögats hornhinna (övergående hornhinnegrumling) gulfärgning av huden eller ögonvitorna (gulsot)
clouding of the eye lens, impaired hearing
Grumling av ögonlinsen, nedsatt hörsel
clouding of the lens (cataract)
grumling av lins (katarakt)
clouding of the lens due to injury (traumatic cataract)
grumling av linsen på grund av skada (traumatisk katarakt)
clouding of the lens due to injury (traumatic cataract),
grumling av linsen på grund av skada (traumatisk katarakt)
Clouding of the lens of the eye.
Grumlig ögonlins.
Clouding of your eye (cataract)
Grumling av ögat (grå starr)
cloudy area in the lens of the eye (cataracts),
grumligt område i ögats lins (katarakt),
Cloudy eyes
Ögongrumling
cloudy lens in the eye (cataract)
grumling av linsen i ögat (katarakt)
clozapine (used to treat psychiatric disorders such as schizophrenia),
klozapin (används vid behandling av psykiska sjukdomar såsom schizofreni),
clozapine - used for some mental health problems
klozapin - används vid vissa mentala hälsoproblem
Clozapine, olanzapine and phenothiazine derivatives – for mental health problems.
Klozapin, olanzapin och fentiazinderivat - vid psykiska sjukdomar.
Clozapine, pimozide Ritonavir co-administration is likely to result in increased plasma concentrations of clozapine or pimozide and is therefore contraindicated (see section 4.3).
Clozapin, pimozid Samtidig administrering med ritonavir förväntas resultera i ökade plasmakoncentrationer av clozapin eller pimozid och är därför kontraindicerat (se avsnitt 4.3).
clozapine, pimozide, (used to treat abnormal thoughts or feelings);
klozapin, pimozid (används för behandling av onormala tankar och känslor);
Clumps, non-uniform solution
Klumpar, ej jämn lösning
Clumsiness
Klumpighet
Clumsiness and lack of coordination affecting balance, walking, limb or eye movements, or speech.
Klumpighet och brist på koordination vilket påverkar balansen, gången, arm- och benrörelser, ögonrörelser eller talet.
Clumsiness;
klumpighet
Cmax
1,13
Cmax
1,38
Cmax (IU/ml)
Cmax (IE/ml)
Cmax (IU/mL)
Cmin (IE/ml)
Cmax (ng/ml) mean (S.D.), range
Cmax (ng/ml) medelvärde (S.D.), spridning
Cmax (peak, g/l)
Cmax (högsta nivå, g/l)
Cmax (µg/ml)
Cmax (g /ml)
Cmax (μg/mL) Mean ± SD
Cmax (μg/ml) Medelvärde ± SD
Cmax (g/ml)
Cmax, g/ml
Cmax 0.95 (0.85, 1.05)
Cmax 0,95 (0,85, 1,05)
Cmax 0.97 (0.89, 1.05)
Cmax 0,97 (0,89, 1,05)
Cmax 1.05 (0.98, 1.12)
AUC 1,10 (1,05, 1,14)
Cmax 1.07 (0.98, 1.16)
AUC 1,07 (1,00, 1,14)
Cmax 1.10 (1.05, 1.16)
AUC 1,01 (0,97, 1,05)
Cmax 1.14 (0.95, 1.36)
Cmax 1,14 (0,95, 1,36)
Cmax 1.15 (1.01, 1.31)
Cmax 1,15 (1,01, 1,31)
Cmax 1.16 (0.82, 1.65)
Cmax 1,16 (0,82, 1,65)
Cmax 1.24 (1.10-1.41)
↑ posakonazol
Cmax 1.26 (0.83, 1.90)
Cmax 1,26 (0,83, 1,90)
Cmax 1.27 (1.07, 1.52)
Cmax 1,27 (1,07, 1,52)
Cmax 1.28 (1.05, 1.55)
Cmax 1,28 (1,05, 1,55)
Cmax 1.46 (0.78, 2.73)
Cmax 1,46 (0,78, 2,73 )
Cmax 1.67 (1.36, 2.05)
Cmax 1,67 (1,36, 2,05)
Cmax 1.95 (1.84, 2.07)
Cmax 1,95 (1,84, 2,07)
Cmax 2.86 (2.52-3.25)
↑ triazolam
Cmax 4.34 (3.10, 6.07)
Cmax 4,34 (3,10, 6,07)
Cmax 5.49 (4.29, 7.04)
Cmax 5,49 (4,29, 7,04)
Cmax 6.24 (4.42, 8.81)
Cmax 6,24 (4,42, 8,81)
Cmax : ↑ 1.8-fold
Cmax : ↑ 1,8-faldig
Cmax = Maximum concentration
Cmax = Maximal koncentration
Cmax after a 10-minute infusion of 6 and 12 mg/m2 body surface area in the target population is approximately 1.5 and 3.5 µg/ml, respectively.
Cmax efter en 10-minuters infusion av 6 respektive 12 mg/ m2 kroppsyta hos målpopulationen är ungefär 1,5 respektive 3,5 µg/ml.
Cmax after a single 10 mg sildenafil dose administered PO was estimated at 24, 53 and 85 ng/ml for 70, 20 and 10 kg patients, respectively.
Cmax efter en engångsdos om 10 mg sildenafil givet peroralt beräknades till 24, 53 och 85 ng/ml för patienter med vikt om 70, 20 respektive 10 kg.
Cmax after a single 20 mg sildenafil dose administered PO was estimated at 49, 104 and 165 ng/ml for 70, 20 and 10 kg patients, respectively.
Cmax efter en engångsdos om 20 mg sildenafil givet peroralt beräknades till 49, 104 och 165 ng/ml för patienter med vikt om 70, 20 respektive 10 kg.
Cmax and AUC (0–tlast) after inhalation of 5 microgram iloprost administered as Ventavis
Cmax och AUC (0-tsista) efter inhalation av 5 mikrogram iloprost administrerat med Ventavis
Cmax and AUC (0–tlast) of iloprost after inhalation with Breelib were, however, still in the range of values observed with Ventavis 10 microgram/ml using other inhalers across different studies.
Cmax och AUC (0-tsista) för iloprost efter inhalation med Breelib var dock fortfarande inom intervallet för värden som observerats med Ventavis 10 mikrogram/ml vid användning av andra inhalatorer i olika studier.
Cmax and AUC are approximately dose-proportional following administration of single and multiple doses.
Cmax och AUC är ungefärligt dosproportionella efter administrering av en enkeldos och efter multipla doser.
Cmax and the area under the plasma concentration-time curve (AUC) increased proportionally up to the highest doses studied (700 mg single-dose and once daily 400 mg multiple doses).
Cmax och arean- under-plasmakoncentrationskurvan (AUC) ökade proportionellt upp till de högsta studerade doserna (700 mg engångsdos och 400 mg en gång dagligen som flera doser).
Cmax and the area under the plasma concentration-time curve were dose proportional.
Cmax och AUC var proportionell mot dosen.
Cmax and the area under the plasma concentration-time curve were dose proportional.
Cmax och AUC var proportionella mot dosen.
Cmax and to a lesser extent AUC increase disproportionately at doses above 40 mg.
Cmax och i mindre utsträckning AUC ökar oproportio- nellt vid doser över 40 mg.
Cmax fold increase
Cmax “faldig” ökning
Cmax following second infusion, was 207 g/mL for the 2 x 500 mg dose and ranged from 377 to 386 g/mL for the 2 x 1000 mg dose.
Efter den andra infusionen var medelvärdet för Cmax 207 µg/mL för dosen 2 x 500 mg respektive varierade mellan 377 och 386 µg/ml för dosen 2 x 1000 mg.
Cmax for fidaxomicin and OP-1118 in plasma were 22% and 33% lower following a high fat meal vs fasting, but the extent of exposure (AUC0-t) was equivalent.
Cmax för fidaxomicin och OP–1118 i plasma var 22 % respektive 33 % lägre efter en fettrik måltid, jämfört med vid fasta, men exponeringsgraden (AUC0-t) var likvärdig.
Cmax for R(+)-warfarin and S(-)-warfarin increased 14% and 15%, respectively.
Cmax för R(+)-warfarin och S(-)-warfarin ökade med 14 procent respektive 15 procent.
Cmax is dose-proportional between 5 and 10 mg.
Cmax är dosproportionellt mellan 5 mg och 10 mg.
Cmax is dose-proportional between 5 and 10 mg.
Cmax är dosproportionellt mellan 5 och 10 mg.
Cmax levels around 500 pg/ml in adults (18-45) versus
Cmax-värden runt 500 pg/ml för vuxna (18–45) gentemot
Cmax ng/ml
Cmax · ng/ml
Cmax of S- and R- warfarin increased 18% and 19%.
Cmax för S- och R-warfarin ökade med 18 % och 19 %.
Cmax ↑ 1.30 (1.17-1.44)
Cmax ↑ 1.30 (1,17-1,44)
Cmax ↓ 0.72 (0.55-0.94) dihydroartemisinin AUC ↓ 0.85 (0.75-0.97)
Cmax ↓ 0,72 (0,55-0,94) dihydroartemisinin AUC ↓ 0,85 (0,75-0,97)
Cmax ↔ 0.91 (0.58-1.42) etravirine
Cmax ↔ 0,91 (0,58-1,42)
Cmax  0% C24  6%
Cmax  0 % C24  6
Cmax  1.29 (0.98-1.68)
C max  1,29 (0,98-1,68)
Cmax  1.29 (0.98-1.68)
Cmax  1,29 (0,98 – 1,68)
Cmax  1.29 (0.98-1.68)
Cmax  1,29 (0,98–1,68)
Cmax  111%
Cmax  111 % .
Cmax  16% Cτ  30% (induction of UGT1A1 and CYP3A enzymes)
Cmax  16 % Cτ  30 % (induktion av enzymerna UGT1A1 och CYP3A)
Cmax  24%
Cmax  24 % Cτ  49
Cmax  37% C24  39% (Complex binding to polyvalent ions)
Cmax  37 % C24  39 % (Komplex som binder till flervärda joner)
Cmax  43% Cτ 72% (induction of UGT1A1 and CYP3A enzymes)
Cmax  43 % Cτ  72 % (induktion av UGT1A1- och CYP3A-enzymer)
Cmax  43% C  72% (induction of UGT1A1 and CYP3A enzymes)
Cmax  43 % C  72 % (induktion av enzymerna UGT1A1 och CYP3A)
Cmax  56% (-70%; -34%)
Cmax  56%(-70%; -34%)
Cmax  57% C24  56% (Complex binding to polyvalent ions)
Cmax  57 % C24  56 % (Komplex som binder till flervärda joner)
Cmax  72% (Complex binding to polyvalent ions)
Cmax  72 % (Komplexbindning till polyvalenta joner)
Cmax, Cmin
ANTIEPILEPTIKA
Cmax, Cmin
ketakonazol exponeringen.
Cmax, Cmin1
NARKOTISKA ANALGETIKA
Cmax: +--
efavirenz.
Cmax: +-- 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (CYP3A4-induktion – effekt på boceprevir)
Cmax: 0 14% (0 3 to 0 24)
Cmax: ↓ 14% (↓ 3 till ↓ 24)
Cmax: 0 15%
Cmax : ↓ 15
Cmax: 0 20% (0 11 to 0 28)
Cmax: ↓ 20% (↓ 11 - ↓ 28)
Cmax: 0 20% (0 15 to 0 24)
Cmax: ↓ 20% (↓ 15 - ↓ 24)
Cmax: 0 21% (0 15 to 0 26)
Cmax: ↓ 21% (↓ 15 - ↓ 26)
Cmax: 0 24% (0 15 to 0 32)
Cmax: ↓ 24% (↓ 15 till ↓ 32)
Cmax: 0 32% (0 15 to 0 46)
Cmax: ↓ 32% (↓ 15 - ↓ 46)
Cmax: 0 35% (0 12 to 0 52)
Cmax: ↓ 35% (↓ 12 - ↓ 52)
Cmax: 0 36% (UGT1A1 induction)
Cmax: ↓ 36% (UGT1A1-induktion)
Cmax: 0 37% (0 20 to 0 51)
Cmax: ↓ 37% (↓ 20 - ↓ 51)
Cmax: 0 44% (0 20 to 0 61)
Cmax: ↓ 44% (↓ 20 - ↓ 61)
Cmax: 0 45% (0 25 to 0 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25 - ↓ 59)
Cmax: 0 45% (UDP-G induction)
(UDP-G-induktion)
Cmax: 0 51% (0 32 to 0 58)
utöver hormonella
Cmax: 0 64% (0 57 to 0 69)
Cmax: ↓ 18% (↓ 59 - ↑ 12)
Cmax: 0 80% (0 77 to 0 83)
Implantat: etonogestrel/efavirenz
Cmax: 1.07 (0.99, 1.16)
0,180/0,215/0,250 mg
Cmax: j 11% (j 3 to j 19) (CYP3A4 induction)
(CYP3A4-induktion)
Cmax: j 14% (j 4 to j 26)
Cmax: ↑ 14% (↑ 4 - ↑ 26)
Cmax: j 16% (j 2 to j 32)
Cmax: ↑ 16% (↑ 2 - ↑ 32)
Cmax: j 21% (j 10 to j 33)
Cmax: ↑ 21% (↑ 10 - ↑ 33)
Cmax: j 23% (0 1 to j 53) * Efavirenz:
Cmax: ↑ 23% (↓ 1 - ↑ 53)
Cmax: j 49% (j 32 to j 69) Efavirenz:
Cmax: ↑ 49% (↑ 32 - ↑ 69)
Cmax: j 50% (j 20 to j 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20 - ↑ 80) (CYP2B6-induktion)
Cmax: j17%* (j8 to j27) Cmin: 042%* (031 to 051)
atazanavir/ritonavir
Cmax: ↑ 1%
Cmax: ↑ 1
Cmax: ↑ 102% (↓ 96 to ↑ 108) Cmin: NC
Cmax: ↑ 102 % (↓ 96 till ↑ 108) Cmin: EB
Cmax: ↑ 102% (↓ 96 – ↑ 108) Cmin: NC
Cmax: ↑ 102 % (↓ 96 till ↑ 108) Cmin: EB
Cmax: ↑ 108%
Cmax: ↑ 108 % Cmin: ↑ 167
Cmax: ↑ 11 % (↑ 3 to ↑ 19)
Cmax: ↑ 11% (↑ 3 - ↑ 19)
Cmax: ↑ 11 % (↑ 6 to ↑ 16)
Cmax: ↑ 11% (↑ 6 - ↑ 16)
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmax: ↑ 11 % (↑ 6 - ↑ 16)
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmax: ↑ 11 % (↑ 6 till ↑ 16)
Cmax: ↑ 14 % (↑ 4 to ↑ 26)
Cmax: ↑ 14% (↑ 4 - ↑ 26)
Cmax: ↑ 14% (↑ 4 to ↑ 26)
Cmax: ↑ 14 % (↑ 4 - ↑ 26)
Cmax: ↑ 14% (↑ 4 to ↑ 26)
Cmax: ↑ 14 % (↑ 4 till ↑ 26)
Cmax: ↑ 15%
Cmax : ↓ 15
Cmax: ↑ 16 % (↑ 2 to ↑ 32)
Cmax: ↑ 16% (↑ 2 - ↑ 32)
Cmax: ↑ 16 % (↑ 6 to ↑ 26)
Cmax: ↑ 16% (↑ 6 - ↑ 26)
Cmax: ↑ 16% (↑ 2 to ↑ 32)
Cmax: ↑ 16 % (↑ 2 - ↑ 32)
Cmax: ↑ 16% (↑ 6 to ↑ 26)
Cmax: ↑ 16 % (↑ 6 - ↑ 26)
Cmax: ↑ 16% (↑ 6 to ↑ 26)
Cmax: ↑ 16 % (↑ 6 till ↑ 26)
Cmax: ↑ 21 % (↑ 10 to ↑ 33)
Cmax: ↑ 21% (↑ 10 - ↑ 33)
Cmax: ↑ 21% (↑ 10 to ↑ 33)
Cmax: ↑ 21 % (↑ 10 - ↑ 33)
Cmax: ↑ 23 % (↓ 1 to ↑ 53) *
Cmax: ↑ 23% (↓ 1 - ↑ 53)
Cmax: ↑ 25% (↑ 8 – ↑ 45) Cmin: ↔
Cmax: ↑ 25 % (↑ 8 till ↑ 45) Cmin: ↔
Cmax: ↑ 3% (↓ 3 – ↑ 9) Cmin: NC
Cmax: ↑ 3 % (↓ 3 till ↑ 9) Cmin: EB
Cmax: ↑ 3.0 fold
Cmax: ↑ 3,0-faldig
Cmax: ↑ 3.4-fold
Cmax: ↑ 3,4-faldig
Cmax: ↑ 3.5-fold
Cmax: ↑ 3,5- gånger
Cmax: ↑ 30% Inhibition of CYP3A
Hämning av CYP3A
Cmax: ↑ 4.1-fold Sirolimus (rapamycin): AUC: ↑ 10.9-fold Cmax: ↑ 4.4-fold
AUC: ↑ 15,3-faldig Cmax: ↑ 4,1-faldig Sirolimus (rapamycin): AUC: ↑ 10,9-faldig Cmax: ↑ 4,4-faldig
Cmax: ↑ 4.7-fold
Cmax: ↑ 4,7-gånger
Cmax: ↑ 41% Cmin: ND
Cmax: ↑ 41 % Cmin: ej fastställd
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmax: ↑ 47 % (↑ 37 till ↑ 58)
Cmax: ↑ 47% (↑ 37 – ↑ 58)
Cmax: ↑ 47 % (↑ 37 till ↑ 58)
Cmax: ↑ 49 % (↑ 32 to ↑ 69)
Cmax: ↑ 49% (↑ 32 - ↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69)
Cmax: ↑ 49 % (↑ 32 - ↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69) Efavirenz:
Cmax: ↑ 49 % (↑ 32 till ↑ 69) Efavirenz:
Cmax: ↑ 5%
AUCtau: ↑ 8 % Cmax: ↑ 5
Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC
Cmax: ↑ 5 % (↓ 3 till ↑ 14) Cmin: EB
Cmax: ↑ 5% (↓ 3 – ↑ 14) Cmin: NC
Cmax: ↑ 5 % (↓ 3 till ↑ 14) Cmin: EB
Cmax: ↑ 50% (↑ 20 to ↑ 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20 - ↑ 80) (CYP2B6-induktion)
Cmax: ↑ 6-fold
Cmax: ↑ 4.7-gånger
Cmax: ↑ 64% (mechanism of interaction unknown)
Cmax: ↑ 64 % (mekanismen för interaktion är okänd)
Cmax: ↑ 64% (mechanism of interaction unknown) Tenofovir:
Cmax: ↑ 64 % (interaktionsmekanismen är inte känd) Tenofovir:
Cmax: ↑ 64% (↑ 54 to ↑ 74)
Cmax: ↑ 64 % (↑ 54 till ↑ 74)
Cmax: ↑ 64% (↑ 54 – ↑ 74)
Cmax: ↑ 64 % (↑ 54 till ↑ 74)
Cmax: ↑ 68% (↑ 54 to ↑ 84)
Cmax: ↑ 68 % (↑ 54 till ↑ 84)
Cmax: ↑ 7% (↓ 6 to ↑ 22) Cmin: NC
Cmax: ↑ 7 % (↓ 6 till ↑ 22) Cmin: EB
Cmax: ↑ 7% (↓ 6 – ↑ 22) Cmin: NC
Cmax: ↑ 7 % (↓ 6 till ↑ 22) Cmin: EB
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmax: ↑ 79 % (↑ 56 till ↑ 104)
Cmax: ↑13% (↑ 1 – ↑ 27) Cmin: NC
Cmax: ↑ 13 % (↑ 1 till ↑ 27) Cmin: EB
Cmax: ↑68% (↑54 – ↑84) Cmin: ↑118% (↑91 – ↑150)
Cmax: ↑ 68 % (↑ 54 till ↑ 84)
Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC
Cmax: ↓ 1 % (↓ 7 till ↑ 6) Cmin: EB
Cmax: ↓ 1% (↓ 7 – ↑ 6) Cmin: NC
Cmax: ↓ 1 % (↓ 7 till ↑ 6) Cmin: EB
Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC
Cmax: ↓ 11 % (↓ 17 till ↓ 5) Cmin: EB
Cmax: ↓ 11% (↓ 17 – ↓ 5) Cmin: NC
Cmax: ↓ 11 % (↓ 17 till ↓ 5) Cmin: EB
Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC
Cmax: ↓ 11 % (↓ 20 till ↑ 1) Cmin: EB
Cmax: ↓ 11% (↓ 20 – ↑ 1) Cmin: NC
Cmax: ↓ 11 % (↓ 20 till ↑ 1) Cmin: EB
Cmax: ↓ 12 % (↓ 1 to ↓ 26) 2-hydroxy atorvastatin:
Cmax: ↓ 12% (↓ 1 - ↓ 26) 2-hydroxiatorvastatin:
Cmax: ↓ 12% (↓ 1 to ↓ 26)
Cmax: ↓ 12 % (↓ 1 - ↓ 26)
Cmax: ↓ 12% (↓ 1 to ↓ 26) 2-hydroxy atorvastatin:
Cmax: ↓ 12 % (↓ 1 till ↓ 26) 2-hydroxyatorvastatin:
Cmax: ↓ 13 % (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4 % (↓ 0 to ↓ 31)
Cmax: ↓ 13% (↓ 0 - ↓ 23) 4-hydroxiatorvastatin: AUC: ↓ 4% (↓ 0 - ↓ 31)
Cmax: ↓ 13% (↓ 0 to ↓ 23)
Cmax: ↓ 13 % (↓ 0 - ↓ 23)
Cmax: ↓ 13% (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4% (↓ 0 to ↓ 31)
Cmax: ↓ 13 % (↓ 0 till ↓ 23) 4-hydroxyatorvastatin: AUC: ↓ 4 % (↓ 0 till ↓ 31)
Cmax: ↓ 13% Cmin: ND
Cmax: ↓ 13 % Cmin: ej fastställd
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14 % (↓ 3 till ↓ 24)
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14% (↓ 3 till ↓ 24)
Cmax: ↓ 15%
Cmax : ↓ 15
Cmax: ↓ 16% (↓ 22 to ↓ 10)
Cmax: ↓ 16 % (↓ 22 till ↓ 10)
Cmax: ↓ 16% (↓ 22 – ↓ 10)
Cmax: ↓ 16 % (↓ 22 till ↓ 10)
Cmax: ↓ 18 % (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59 - ↑ 12)
Cmax: ↓ 18% (↓ 59 to ↑ 12)
Cmax: ↓ 18 % (↓ 59 - ↑ 12)
Cmax: ↓ 18% (↓ 59 to ↑ 12)
Cmax: ↓ 18 % (↓ 59 till ↑ 12)
Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-3310071:
Cmax: ↓ 19 % (↓ 40 till ↑ 10) GS-3310071:
Cmax: ↓ 19% (↓ 40 – ↑ 10)
Cmax: ↓ 19 % (↓ 40 till ↑ 10)
Cmax: ↓ 20 % (↓ 11 to ↓ 28)
Cmax: ↓ 20% (↓ 11 - ↓ 28)
Cmax: ↓ 20 % (↓ 15 to ↓ 24)
Cmax: ↓ 20% (↓ 15 - ↓ 24)
Cmax: ↓ 20 % (↓ 2 to ↓ 26)
Cmax: ↓ 20% (↓ 2 - ↓ 26)
Cmax: ↓ 20% (↓ 11 to ↓ 28)
Cmax: ↓ 20 % (↓ 11 - ↓ 28)
Cmax: ↓ 20% (↓ 11 to ↓ 28)
Cmax: ↓ 20 % (↓ 11 till ↓ 28)
Cmax: ↓ 20% (↓ 15 to ↓ 24)
Cmax: ↓ 20 % (↓ 15 - ↓ 24)
Cmax: ↓ 20% (↓ 15 to ↓ 24)
Cmax: ↓ 20 % (↓ 15 till ↓ 24)
Cmax: ↓ 20% (↓ 2 to ↓ 26)
Cmax: ↓ 20 % (↓ 2 - ↓ 26)
Cmax: ↓ 20% (↓ 2 to ↓ 26)
Cmax: ↓ 20 % (↓ 2 till ↓ 26)
Cmax: ↓ 21 % (↓ 15 to ↓ 26)
Cmax: ↓ 21% (↓ 15 - ↓ 26)
Cmax: ↓ 21% (↓ 15 to ↓ 26)
Cmax: ↓ 21 % (↓ 15 - ↓ 26)
Cmax: ↓ 21% (↓ 15 to ↓ 26)
Cmax: ↓ 21 % (↓ 15 till ↓ 26)
Cmax: ↓ 23% (↓ 30 to ↑ 16) Efavirenz:
Cmax: ↓ 23 % (↓ 30 till ↑ 16) Efavirenz:
Cmax: ↓ 23% (↓ 30 – ↑ 16)
Cmax: ↓ 23 % (↓ 30 till ↑ 16)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24 % (↓ 15 till ↓ 32)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24% (↓ 15 till ↓ 32)
Cmax: ↓ 24% (↓ 18 to ↓ 30)
Cmax: ↓ 24 % (↓ 18 - ↓ 30)
Cmax: ↓ 24% (↓ 44 –↓ 12) Cmin: NC
Cmax: ↓ 24 % (↓ 44 till ↓ 12) Cmin: EB
Cmax: ↓ 26 % (↓ 15 to ↓ 35)
Cmax : ↓ 26% (↓ 15 - ↓ 35)
Cmax: ↓ 26 % (↓ 15 to ↓ 35) Clarithromycin
Cmax : ↓ 26% (↓ 15 - ↓ 35)
Cmax: ↓ 26% (↓ 15 to ↓ 35)
Cmax : ↓ 26 % (↓ 15 - ↓ 35)
Cmax: ↓ 26% (↓ 15 to ↓ 35) Clarithromycin
Cmax: ↓ 26 % (↓ 15 till ↓ 35) Klaritromycin
Cmax: ↓ 28 % (↓ 7 to ↓ 44)
Cmax: ↓ 28% (↓ 7 - ↓ 44)
Cmax: ↓ 28% (↓ 50 to ↑ 5)
Cmax: ↓ 28 % (↓ 50 till ↑ 5)
Cmax: ↓ 28% (↓ 50 – ↑ 5)
Cmax: ↓ 28 % (↓ 50 till ↑ 5)
Cmax: ↓ 28% (↓ 7 to ↓ 44)
Cmax: ↓ 28 % (↓ 7 - ↓ 44)
Cmax: ↓ 28% (↓ 7 to ↓ 44)
Cmax: ↓ 28 % (↓ 7 till ↓ 44)
Cmax: ↓ 29 % (↓ 15 to ↓ 40)
Cmax: ↓ 29% (↓ 15 - ↓ 40)
Cmax: ↓ 29% (↓ 15 to ↓ 40)
Cmax: ↓ 29 % (↓ 15 - ↓ 40)
Cmax: ↓ 29% (↓ 15 to ↓ 40)
Cmax: ↓ 29 % (↓ 15 till ↓ 40)
Cmax: ↓ 32 % (↓ 15 to ↓ 46)
Cmax: ↓ 32% (↓ 15 - ↓ 46)
Cmax: ↓ 32% (↓ 15 to ↓ 46)
Cmax: ↓ 32 % (↓ 15 - ↓ 46)
Cmax: ↓ 32% (↓ 15 to ↓ 46)
Cmax: ↓ 32 % (↓ 15 till ↓ 46)
Cmax: ↓ 33% (Mechanism unknown)
(Okänd mekanism)
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 34 % (↓ 21 till ↓ 47) Hydroxibupropion:
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 34% (↓ 21 - ↓ 47) hydroxibupropion:
Cmax: ↓ 34% (↓ 41 to ↑ 25)
Cmax: ↓ 34 % (↓ 41 till ↑ 25)
Cmax: ↓ 34% (↓ 41 – ↑ 25)
Cmax: ↓ 34 % (↓ 41 till ↑ 25)
Cmax: ↓ 35 % (↓ 12 to ↓ 52)
Cmax: ↓ 35% (↓ 12 - ↓ 52)
Cmax: ↓ 35% (↓ 12 to ↓ 52)
Cmax: ↓ 35 % (↓ 12 - ↓ 52)
Cmax: ↓ 35% (↓ 12 to ↓ 52)
Cmax: ↓ 35 % (↓ 12 till ↓ 52)
Cmax: ↓ 36 % (UGT1A1 induction)
Cmax: ↓ 36% (UGT1A1-induktion)
Cmax: ↓ 36% (UGT1A1 induction)
Cmax: ↓ 36 % (UGT1A1-induktion)
Cmax: ↓ 37 % (↓ 20 to ↓ 51)
Cmax: ↓ 37% (↓ 20 - ↓ 51)
Cmax: ↓ 37% (↓ 20 to ↓ 51)
Cmax: ↓ 37 % (↓ 20 - ↓ 51)
Cmax: ↓ 37% (↓ 20 to ↓ 51)
Cmax: ↓ 37 % (↓ 20 till ↓ 51)
Cmax: ↓ 37% (↓ 48 to ↓ 25)
Cmax: ↓ 37 % (↓ 48 till ↓ 25)
Cmax: ↓ 37% (↓ 48 – ↓ 25)
Cmax: ↓ 37 % (↓ 48 till ↓ 25)
Cmax: ↓ 38% Lumefantrine: AUC: ↓ 21%
Cmax: ↓ 38 % Lumefantrin: AUC: ↓ 21
Cmax: ↓ 4% (CYP3A4 inhibition)
Cmax: ↓ 4 % (CYP3A4-hämning)
Cmax: ↓ 4% (↓ 9 to ↑ 2) Cmin: NC
Cmax: ↓ 4 % (↓ 9 till ↑ 2) Cmin: EB
Cmax: ↓ 4% (↓ 9 – ↑ 2) Cmin: NC
Cmax: ↓ 4 % (↓ 9 till ↑ 2) Cmin: EB
Cmax: ↓ 44% (↓ 20 to ↓ 61) Proguanil:
Cmax: ↓ 44 % (↓ 20 till ↓ 61) Proguanil:
Cmax: ↓ 45 % (UDP-G induction)
Cmax: ↓ 45% (UDP-G-induktion)
Cmax: ↓ 45 % (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25 - ↓ 59)
Cmax: ↓ 45% (UDP-G induction)
Cmax: ↓ 45 % (UDP-G induktion)
Cmax: ↓ 45% (UDP-G induction)
Cmax: ↓ 45 % (UDP-G-induktion)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45 % (↓ 25 - ↓ 59)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45 % (↓ 25 till ↓ 59) (CYP3A4-induktion)
Cmax: ↓ 46 % (↓ 39 to ↓ 52)
Cmax: ↓ 46% (↓ 39 till ↓ 52)
Cmax: ↓ 46% (↓ 39 to ↓ 52)
Cmax: ↓ 46 % (↓ 39 till ↓ 52)
Cmax: ↓ 47 % (↓ 9 to ↓ 51)
Cmax: ↓ 47% (↓ 9 - ↓ 51)
Cmax: ↓ 47% (↓ 9 to ↓ 51)
Cmax: ↓ 47 % (↓ 9 - ↓ 51)
Cmax: ↓ 5% (↓ 11 to ↑ 1) Cmin: NC
Cmax: ↓ 5 % (↓ 11 till ↑ 1) Cmin: EB
Cmax: ↓ 5% (↓ 11 to ↑ 1) Cmin: NC
Cmax: ↓ 5 % (↓ 27 till ↑ 24) Cmin: EB
Cmax: ↓ 5% (↓ 11 – ↑ 1) Cmin: NC
Cmax: ↓ 5 % (↓ 11 till ↑ 1) Cmin: EB
Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Cmax: ↑ 3 % (↓ 3 till ↑ 9) Cmin: EB
Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Cmax: ↓ 5 % (↓ 27 till ↑ 24) Cmin: EB
Cmax: ↓ 5% (↓ 27 – ↑ 24) Cmin: NC
Cmax: ↓ 5 % (↓ 27 till ↑ 24) Cmin: EB
Cmax: ↓ 50%
riskerna för systemeffekter av
Cmax: ↓ 51 % (↓ 32 to ↓ 58)
Cmax: ↓ 51% (↓ 32 - ↓ 58)
Cmax: ↓ 51 % (↓ 37 to ↓ 62)
C12: ↓ 21
Cmax: ↓ 51 % (↓ 37 to ↓ 62) Efavirenz concentrations not measured, no effect is expected.
Cmax: ↓ 51% (↓ 37 till ↓ 62) Efavirenzkoncentrationer har inte mätts, ingen effekt förväntas.
Cmax: ↓ 51% (↓ 32 to ↓ 58)
Cmax: ↓ 51 % (↓ 32 - ↓ 58)
Cmax: ↓ 51% (↓ 37 to ↓ 62) Efavirenz concentrations not measured, no effect is expected.
Cmax: ↓ 51 % (↓ 37 till ↓ 62) Efavirenzkoncentrationer har inte mätts, ingen effekt förväntas.
Cmax: ↓ 51% (↓ 37 to ↓ 62) Efavirenz concentrations not measured, no effect is expected.
Cmax: ↓ 51 % (↓ 37 till ↓ 62) Efavirenzkoncentrationerna inte uppmätta, ingen effekt förväntas.
Cmax: ↓ 51% (↓ 46 to ↓ 56)
Cmax: ↓ 51 % (↓ 46 till ↓ 56)
Cmax: ↓ 51% (↓ 46 to ↓ 56)
Cmax: ↓ 51% (↓ 46 till ↓ 56)
Cmax: ↓ 6% (↓ 13 to ↑ 0)
AUC: ↑ 6 % (↓ 1 till ↑ 13)
Cmax: ↓ 6% (↓ 13 to ↑ 0)
Cmax: ↓ 6 % (↓ 13 till ↑ 0)
Cmax: ↓ 6% (↓ 13 – ↑ 0)
Cmax: ↓ 6 % (↓ 13 till ↑ 0)
Cmax: ↓ 60 % (↓ 50 to ↓ 68)
Cmax: ↓ 60% (↓ 50 - ↓ 68)
Cmax: ↓ 60% (↓ 50 to ↓ 68)
Cmax: ↓ 60 % (↓ 50 - ↓ 68)
Cmax: ↓ 60% (↓ 50 to ↓ 68)
Cmax: ↓ 60 % (↓ 50 till ↓ 68)
Cmax: ↓ 61% Efavirenz: AUC: ↑ 44%
Cmax: ↓ 61 % Efavirenz: AUC: ↑ 44
Cmax: ↓ 62% (↓ 55 to ↓ 78) (CYP3A4 induction)
Cmax: ↓ 62 % (↓ 55 till ↓ 78) (CYP3A4-induktion)
Cmax: ↓ 64 % (↓ 57 to ↓ 69)
Cmax: ↓ 64% (↓ 57 - ↓ 69)
Cmax: ↓ 64% (↓ 57 to ↓ 69)
Cmax: ↓ 64 % (↓ 57 - ↓ 69)
Cmax: ↓ 64% (↓ 57 to ↓ 69)
Cmax: ↓ 64 % (↓ 57 till ↓ 69)
Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Cmax: ↓ 7 % (↓ 13 till ↓ 0) Cmin: EB